| Literature DB >> 34717632 |
Yeong Hwan Kim1, Gwang-Bum Im1, Sung-Won Kim1, Yu-Jin Kim1, Taekyung Yu2, Ju-Ro Lee3, Soong Ho Um1, Yoon Ki Joung3,4, Suk Ho Bhang5.
Abstract
BACKGROUND: Human adipose-derived stem cells (hADSCs) have been used in various fields of tissue engineering because of their promising therapeutic efficacy. However, the stemness of hADSCs cannot be maintained for long durations, and their therapeutic cellular functions, such as paracrine factor secretion decrease during long-term cell culture. To facilitate the use of long-term-cultured hADSCs (L-ADSCs), we designed a novel therapeutic anti-senescence ion-delivering nanocarrier (AIN) that is capable of recovering the therapeutic properties of L-ADSCs. In the present study, we introduced a low-pH-responsive ion nanocarrier capable of delivering transition metal ions that can enhance angiogenic paracrine factor secretion from L-ADSCs. The AINs were delivered to L-ADSCs in an intracellular manner through endocytosis.Entities:
Keywords: Angiogenesis; Functionality restoring; Intracellular ion delivery; Ischemic disease; Senescence; Stem cell therapy
Mesh:
Substances:
Year: 2021 PMID: 34717632 PMCID: PMC8557526 DOI: 10.1186/s12951-021-01098-7
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 10.435
Fig. 1Physical and chemical properties of anti-senescence ion-delivering nanocarriers (AINs). A A transmission electron microscopy (TEM) image of AINs (high power magnification at the top-left corner). B Size distribution of AINs, as measured using TEM. C Energy-dispersive X-ray spectroscopy (EDXS) analysis of AINs. Iron atom peaks are indicated with white arrows. D X-ray diffraction (XRD) patterns of AINs. Iron ion patterns are emphasized using blue squares. E Ultraviolet-visible spectroscopy (UV-Vis) spectra of AINs at pH 7.0 (blue line), gold nanoparticles (Au) at pH 7.0 (red line), and AINs at pH 4.5 (black line). Peak shifts owing to the present of iron. F The component gold/iron ratio profile of AINs as estimated using EDXS under the different pH conditions at 12 h (n = 3, *p < 0.05 versus standard group)
Fig. 2Optimization of the concentration of AINs used for treatment of L-ADSCs. A Cell viability of L-ADSCs after treatment with AINs (n = 4, **p < 0.01 versus no treatment group). B Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay examining AIN treated L-ADSCs (blue: nucleus, green: apoptotic cell). White arrows indicate cells undergoing apoptosis that was induced by AINs. Scale bar: 100 μm. C Fluorescein diacetate/ethidium (FDA/EB) staining of L-ADSCs post-treatment with AINs (green: live cells, red: dead cells). Scale bar: 100 μm. D DiI staining of L-ADSCs treated with AINs (blue: nucleus, red: cellular membrane). Scale bar: 100 μm. E Relative mRNA expression levels of VEGF and FGF2 in L-ADSCs at 3, 6, 9, and 12 h after treatment with various concentration of AINs (n = 4, *p < 0.05 and **p < 0.01 versus no treatment group, #p < 0.05 and ##p < 0.01 versus each group). Relative mRNA expression of F the apoptosis-related genes BAX and CASPASE3 and G the proliferation-related genes KI-67 and PCNA in L-ADSCs after treatment with various concentrations of AINs (n = 3, **p < 0.01 and ***p < 0.001 versus no treatment group)
Fig. 3Cellular uptake and effects of AINs in L-ADSCs. A Schematic representation of the functionality-restoring effects of AINs. B TEM images of L-ADSCs after treatment with AINs for 12 h (N: nucleus, red arrow: intracellular AINs). C Mass detection of iron in L-ADSCs with or without AIN treatment as quantified using inductively coupled plasma optical emission spectrometer (ICP-OES; n = 4). D Mass detection of iron ions in CM harvested from L-ADSCs at passage 15 without AIN treatment (15 N-CM) and from L-ADSCs at passage 15 with AIN treatment (15 A-CM) as quantified by ICP-OES (n = 4). E Heat map image of the expression levels of senescence-related and stemness-related genes. F Relative mRNA expression of the senescence-related genes P21, P53, and P16 in L-ADSCs with or without AINs treatment (n = 4). G Relative mRNA expression of the stemness-related genes NANOG, OCT4, KLF4, and SOX2 in L-ADSCs with or without AIN treatment (n = 4). H Relative mRNA expression of chondrogenesis-related and adipogenesis-related genes in L-ADSCs with or without AIN treatment (n = 4). (#p < 0.05, ##p < 0.01, and ###p < 0.001 versus each group)
Fig. 4Enhanced angiogenic potency of AINs-treated L-ADSCs. A Quantification of human VEGF and FGF2 protein secretion within CM harvested from S-ADSCs at passage 7 without AIN treatment (7 N-CM, 15 N-CM, and 15 A-CM) as evaluated using enzyme-linked immunosorbent assay (ELISA; n = 4, **p < 0.01 versus no treatment group, #p < 0.01 versus each group). B Representative profiles of angiogenesis-related proteins secreted from 7 N-CM, 15 N-CM, and 15 A-CM as evaluated using a human angiogenesis antibody array. C Relative mRNA expression of CXCL12 in S-ADSCs and in L-ADSCs with or without AINs treatment. as quantified using qRT-PCR after treatment with AINs for 12 h (n = 4, **p < 0.01 versus no treatment group). D Representative images of scratched area and relative cell migration area after treatment with 7 N-CM, 15 N-CM, and 15 A-CM as analyzed using a scratch wound assay (red area indicates the scratched area, n = 4, **p < 0.01 versus no treatment group)
Fig. 5Increased wound-healing effect of 15 A-CM at 14 d after treatment. A Images of wounds and wound-closing percentages at 14 d after treatment with CM (n = 5, ##p < 0.01 versus other groups). B Representative images and quantification of muscle regeneration at 14 d after treatment with CM (n = 3, ###p < 0.001 versus other groups). Representative histological images of C hematoxylin and eosin (H&E) and D Masson’s trichrome (MT) staining of wounds at 14 d after treatment with CM
Fig. 6Improved angiogenesis and dermal regeneration at 14 d after 15 A-CM treatment within the wound tissue. A Analysis of a vascular marker (CD31) using qRT-PCR and immunostaining (n = 3, blue: nucleus, green: CD31). B Analysis of a representative dermis marker (laminin) using qRT-PCR and immunostaining (n = 3, blue: nucleus, green: laminin). C Analysis of a representative epidermis marker (involucrin) using qRT-PCR and immunostaining (n = 3, blue: nucleus, green: involurin) (#p < 0.05, ##p < 0.01, and ###p < 0.001 versus each group)
Sequences of qRT-PCR primers
| Primer | Sequence | |
|---|---|---|
Human
| Forward | 5′-GTC GGA GTC AAC GGA TTT GG-3′ |
| Reverse | 5′-GGG TGG AAT CAA TTG GAA CAT-3′ | |
Human
| Forward | 5′-GAG GGC AGA ATC ATC ACG AAG T-3′ |
| Reverse | 5′-CAC CAG GGT CTC GAT TGG AT-3′ | |
Human
| Forward | 5′-GAC GGC AGA GTT GAC GG-3′ |
| Reverse | 5′-CTC TCT CTT CTG CTT GAA GTT-3′ | |
Human
| Forward | 5′-GCA ACT TCA ACT GGG GCC GGG-3′ |
| Reverse | 5′- GAT CCA GCC CAA CAG CCG CTC-3′ | |
Human
| Forward | 5′-CCT GGT TAT TAT TCT TGG CGA AA-3′ |
| Reverse | 5′-GCA CAA AGC GAC TGG ATG AA-3′ | |
Human
| Forward | 5′-CCA CAC TGT GTC GTC GTT TG-3′ |
| Reverse | 5′-CCG TGC GCT TAT CCA TTC A-3′ | |
Human
| Forward | 5′-CCT GCT GGG ATA TTA GCT CCA-3′ |
| Reverse | 5′-CAG CGG TAG GTG TCG AAG C-3′ | |
Human
| Forward | 5’-TGA GCC GCG ACT GTG ATG-3’ |
| Reverse | 5′-GTC TCG GTG ACA AAG TCG AAG TT-3′ | |
Human
| Forward | 5′-CCT CAG CAT CTT ATC CGA GTG G-3′ |
| Reverse | 5′-TGG ATG GTG GTA CAG TCA GAG C-3′ | |
Human
| Forward | 5′-ACT TCA GGG GTG CCA CAT TC-3′ |
| Reverse | 5′-CGA CCC TGT CCC TCA AAT CC-3′ | |
Human
| Forward | 5′-AGT CCC AAA GGC AAA CAA CCC ACT TC-3′ |
| Reverse | 5′-TGC TGG AGG CTG AGG TAT TTC TGT CTC-3′ | |
Human
| Forward | 5′-CTG GGT TGA TCC TCG GAC CT-3′ |
| Reverse | 5′-CAC AGA ACT CAT ACG GCG GG -3′ | |
Human
| Forward | 5′-TCT CAA GGC AGA CCT GCG AA-3′ |
| Reverse | 5′-TAG TGC CTG GTC AGT TCA TC-3′ | |
Human
| Forward | 5′-TGA TGG AGA CGG AGC TGA A-3′ |
| Reverse | 5′-GGG CTG TTT TTC TGG TTG C-3′ | |
Human
| Forward | 5′-CCC AGC ATC TGC AAA GCT C-3′ |
| Reverse | 5′-GTC AAT GTA CAG CTG CCG CA-3′ | |
Human
| Forward | 5′-TTG TGC CTT GGA AAT GCA AAC-3′ |
| Reverse | 5′-TCG GGA AGG AGG CAG GAA AC-3′ | |
Human
| Forward | 5′-TGC CAG AGC CAA CGT CAA G-3′ |
| Reverse | 5′-CAG CCG GGC TAC AAT CTG AA-3′ | |
Mouse
| Forward | 5′-GGC TGT ATT CCC CTC CAT CG-3′ |
| Reverse | 5′-CCA GTT GGT AAC AAT GCC ATG T-3′ | |
Mouse
| Forward | 5′-CAA ACA GAA ACC CGT GGA GAT G-3′ |
| Reverse | 5′-ACC GTA ATG GCT GTT GGC TTC-3′ | |
Mouse
| Forward | 5′-GGA CGG GAA TTC CGT TAG GG-3′ |
| Reverse | 5′-CAG GTC CAA GGA CTG CAC TT-3′ | |
Mouse
| Forward | 5′-CCT GTG AGT TTG TTT GGT CTA CA-3′ |
| Reverse | 5′-GAA CCA CAG CTG GAA CAG TC-3′ | |